Latest news
Akamai Technologies Drops 5.3% After Guggenheim Maintains Buy - AlphaStreetAlphaStreet · Fri, 07 Aug 2026 21:32:58 GMTGuggenheim Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Cuts Target Price to $48 - MoomooMoomoo · Fri, 07 Aug 2026 13:37:00 GMTGuggenheim Adjusts Incyte Price Target to $150 From $136, Maintains Buy Rating - marketscreener.commarketscreener.com · Wed, 29 Jul 2026 13:00:55 GMT